Company profile: AveXis

1.1 - Company Overview

AveXis

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of gene therapies specializing in the development and commercialization for patients and families affected by rare and life-threatening neurological genetic diseases; doing business as Novartis Gene Therapies, Inc. following Novartis’s 2018 acquisition and 2020 renaming.

Products and services

🔒

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to AveXis

Audentes Therapeutics

HQ: United States Website

Description: Provider of gene therapy research and development for rare muscle diseases, serving as the Gene Therapy Center of Excellence with divisions in technical operations, medical and development, and future commercialization of gene therapy programs.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Audentes Therapeutics company profile →

Aeglea BioTherapeutics

HQ: United States Website

Description: Provider of clinical-stage enzyme therapies for rare metabolic diseases and investigational monoclonal antibody programs for IBD, including SPY001 targeting α4β7 integrin and SPY002 targeting TL1A, with rational combination studies (SPY120, SPY130, SPY230) and precision immunology approaches using genetic or biomarker-based patient selection.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Aeglea BioTherapeutics company profile →

Therachon

HQ: Switzerland Website

Description: Provider of biotechnology-based medicines for rare genetic diseases with no available treatments, including TA-46, a novel protein therapy in development for achondroplasia.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Therachon company profile →

Eidos Therapeutics

HQ: United States Website

Description: Provider of clinical-stage biotechnology research and development of novel, genetically targeted therapies to improve the lives of patients.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Eidos Therapeutics company profile →

Oxyrane

HQ: United Kingdom Website

Description: Provider of novel and biosuperior enzyme replacement therapies for lysosomal storage diseases. Pipeline includes OxyGCase for neuronopathic Gaucher disease and OXY2810 for Pompe disease. Offers the OxyCAT glycoengineered yeast-based platform to produce ERTs with enhanced cellular uptake and pharmacodynamics.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Oxyrane company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for AveXis

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to AveXis

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in AveXis's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in AveXis's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to AveXis

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in AveXis's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in AveXis's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for AveXis

4.2 - Public trading comparable groups for AveXis

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to AveXis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About AveXis

What does AveXis do?

AveXis is a provider of gene therapies specializing in the development and commercialization for patients and families affected by rare and life-threatening neurological genetic diseases; doing business as Novartis Gene Therapies, Inc. following Novartis’s 2018 acquisition and 2020 renaming.

Who are AveXis's competitors?

AveXis's competitors and similar companies include Audentes Therapeutics, Aeglea BioTherapeutics, Therachon, Eidos Therapeutics, and Oxyrane.

Where is AveXis headquartered?

AveXis is headquartered in United States.

How many employees does AveXis have?

AveXis has 1,000 employees 🔒.

When was AveXis founded?

AveXis was founded in 2010 🔒.

What sector and industry vertical is AveXis in?

AveXis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for AveXis

Who are the top strategic acquirers in AveXis's sector and industry

Top strategic M&A buyers and acquirers in AveXis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for AveXis?

Top strategic M&A buyers groups and sectors for AveXis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in AveXis's sector and industry vertical

Which are the top PE firms investing in AveXis's sector and industry vertical?

Top PE firms investing in AveXis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in AveXis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in AveXis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in AveXis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to AveXis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in AveXis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for AveXis?

The key public trading comparables and valuation benchmarks for AveXis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for AveXis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for AveXis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in AveXis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for AveXis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in AveXis's' sector and industry vertical?

Access recent funding rounds and capital raises in AveXis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for AveXis

Start Free Trial Book a Demo